



1631

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**(To be used for all correspondence
after initial filing)

Application Number	09/827,271
Filing Date	April 4, 2001
First Named Inventor	Marc W. Retter
Group Art Unit	1631
Examiner Name	
Attorney Docket No.	210121.462C6

RECEIVED



MAR 18 2003

ENCLOSURES (check all that apply)**TECH CENTER 1600/2900**


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement; Form PTO-1449 <input checked="" type="checkbox"/> Cited References (8) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
--	---	--

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	William T. Christiansen, Ph.D. 44,614	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	March 12, 2003	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.		
Typed or printed name	Lawrence Teague	
Signature		Date: March 12, 2003



PATENT

#7
3-19-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marc W. Retter and Gary R. Fanger
Application No. : 09/827,271
Filed : April 4, 2001
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF OVARIAN CANCER

Art Unit : 1631
Docket No. : 210121.462C6
Date : March 12, 2003

RECEIVED

MAR 17 2003

TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Second Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



William T. Christiansen, Ph.D.

Registration No. 44,614

JEH:ljt

Enclosures:

Postcard
Form PTO/SB/21
Form PTO-1449
Cited References (8)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.462C6

APPLICATION NO.

09/827,271

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Marc W. Retter and Gary R. Fanger

FILING DATE

April 4, 2001

GROUP ART UNIT

1631

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
AB	WO 00/36107	06/22/00	WIPO	
AC				
AD				

RECEIVED

MAR 18 2003

TECH CENTER 1600/2900

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AE	Hovig, E. et al., "CA 125: The End of the Beginning," <i>Tumor Biology</i> 22: 345-347, 2001.
AF	O'Brien, T.J. et al., "The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure," <i>Tumor Biology</i> 23: 154-169, 2002.
AG	O'Brien, T.J. et al., "The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences," <i>Tumor Biology</i> 22: 348-366, 2001.
AH	Schummer, M. et al., "Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas," <i>Gene</i> 238: 375-385, 1999.
AI	Whitehouse, C. et al., "NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube," <i>Eur. J. Biochem.</i> 269: 538-545, 2002.
AJ	Yin and Lloyd, "Molecular Cloning of the CA125 Ovarian Cancer Antigen. Identification as a new mucin, MUC16," <i>Journal of Biological Chemistry</i> 276(29): 27371-27375, July 20, 2001.
AK	Yin, B.W.T. et al., "Ovarian cancer antigen CA125 is encoded by the <i>MUC16</i> mucin gene," <i>International Journal of Cancer</i> 98: 737-740, 2002.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).